Clinical Trials Browser

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

Clinical Trials

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

MK-5684-004

TRIPLE-SWITCH

Radium-223 in Combination With Enzalutamide

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

DICE

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

IDeate-Prostate02

VA STARPORT

OMAHA-003

InavoPC

TALAPRO-2

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

PREDICT

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

EvoPAR-PR01

Pan Tumor Rollover Study

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

MEVPRO-3

Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

KEYNOTE-991

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

ARAMON

CELLO-1

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

MEVPRO-1

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

ARCH

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

Tivozanib + Enzalutamide in Adv Prostate Cancer

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

AMX-500

AcTFirst

KEYNOTE-365

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression